Literature DB >> 26303454

Clinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery.

Vishesh Khanna1, Sangeeta R Kashyap.   

Abstract

Bariatric surgery has emerged as an effective treatment for type 2 diabetes in the setting of obesity, with recent clinical trials demonstrating biochemical remission (i.e., euglycemia) in up to 40 % of subjects at 3 years post-surgery. Conversely, these trials also highlight that a significant proportion of individuals undergoing bariatric surgery experience residual diabetes (i.e., they do not achieve remission or experience diabetes recurrence). The management of residual diabetes following surgery requires personalized attention, yet limited evidence exists on which to base clinical decisions. Hence, we aim to review the evidence that does exist and propose clinical management strategies in patients with persistent hyperglycemia following bariatric surgery.

Entities:  

Mesh:

Year:  2015        PMID: 26303454     DOI: 10.1007/s11883-015-0537-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  66 in total

Review 1.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

2.  Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.

Authors:  G Derosa; A F G Cicero; A D'Angelo; E Fogari; P Maffioli
Journal:  J Clin Pharm Ther       Date:  2011-08-04       Impact factor: 2.512

3.  Bariatric surgery for diabetes: the International Diabetes Federation takes a position.

Authors:  John B Dixon; Paul Zimmet; K George Alberti; Jean Claude Mbanya; Francesco Rubino
Journal:  J Diabetes       Date:  2011-12       Impact factor: 4.006

4.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.

Authors:  Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-03-31       Impact factor: 91.245

Review 5.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Authors:  Steven E Kahn; Mark E Cooper; Stefano Del Prato
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

6.  Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  M Monami; C Nardini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-12-29       Impact factor: 6.577

7.  Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.

Authors:  S R Smith; K Fujioka; A K Gupta; S K Billes; C Burns; D Kim; E Dunayevich; F L Greenway
Journal:  Diabetes Obes Metab       Date:  2013-04-05       Impact factor: 6.577

8.  Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.

Authors:  Z Punthakee; N Alméras; J-P Després; G R Dagenais; S S Anand; D L Hunt; A M Sharma; H Jung; S Yusuf; H C Gerstein
Journal:  Diabet Med       Date:  2014-06-19       Impact factor: 4.359

Review 9.  Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.

Authors:  André J Scheen; Luc F Van Gaal
Journal:  Lancet Diabetes Endocrinol       Date:  2014-02-19       Impact factor: 32.069

10.  GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats.

Authors:  Kirk M Habegger; Henriette Kirchner; Chun-Xia Yi; Kristy M Heppner; Dan Sweeney; Nickki Ottaway; Jenna Holland; Sarah Amburgy; Christine Raver; Radhakrishna Krishna; Timo D Müller; Diego Perez-Tilve; Paul T Pfluger; Silvana Obici; Richard D DiMarchi; David A D'Alessio; Randy J Seeley; Matthias H Tschöp
Journal:  Diabetes       Date:  2013-06-17       Impact factor: 9.461

View more
  2 in total

Review 1.  Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations.

Authors:  A Thorell; A D MacCormick; S Awad; N Reynolds; D Roulin; N Demartines; M Vignaud; A Alvarez; P M Singh; D N Lobo
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

2.  The Role of Laboratory Testing in Differentiating Type 1 Diabetes from Type 2 Diabetes in Patients Undergoing Bariatric Surgery.

Authors:  Scott J Pilla; Nisa M Maruthur; Michael A Schweitzer; Thomas H Magnuson; James J Potter; Jeanne M Clark; Clare J Lee
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.